Great Friday
SNT are attracting attention , we have been approached by commercial partners for over a year , meeting with potential partners in the weekend..
Next Month there is a Partnering Event ...
Our Trial Participants were significantly effected by Myelofibrosis prior to Trial Commencement ...
Brief notes jotted down
25% reduction in spleen inflammation
5505 works in combination with current SOC
We are not competing but adding to overall care
Our Market opportunity looks to be over 1$B
Initiates new cell growth
Activated Immune Cells to assist with healing
Reduced inflamation
Our Patients were very ill ,,sub optimal Patients ,, looking to recruit a greater mix of recently diagnosed patients
Patients are still improving on symptom scores
SNT 5505 beats current care and those under development
Comparisons shows at Phase II $1.1B milestone with a $200m upfront payment
The longer we trial the higher the value
$18m in cash , we were burning $1m per month but that should drop
UK Parkinson Trial fully externally funded
FDA to assist with Fast Track Trial Design Outcome from Phase III design with FDA will be announced
Biggest selling drug patent expires in 2028,, Patient cost is $250k USD per year,, SNT 5505 can assist to extend that Patent ..
Gary seemed genuinely excited ,, adrenalin fueled ..
right time for lunch NZT
Add to My Watchlist
What is My Watchlist?
